Organovo (VIVS) Competitors $1.79 +0.04 (+2.29%) As of 01:45 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock VIVS vs. COCP, ALLR, MEIP, EQ, EDSA, ALVR, NXTC, ME, IBIO, and RLYBShould you be buying Organovo stock or one of its competitors? The main competitors of Organovo include Cocrystal Pharma (COCP), Allarity Therapeutics (ALLR), MEI Pharma (MEIP), Equillium (EQ), Edesa Biotech (EDSA), AlloVir (ALVR), NextCure (NXTC), 23andMe (ME), iBio (IBIO), and Rallybio (RLYB). These companies are all part of the "pharmaceutical products" industry. Organovo vs. Cocrystal Pharma Allarity Therapeutics MEI Pharma Equillium Edesa Biotech AlloVir NextCure 23andMe iBio Rallybio Cocrystal Pharma (NASDAQ:COCP) and Organovo (NASDAQ:VIVS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, community ranking, profitability, institutional ownership, risk, analyst recommendations and valuation. Do analysts recommend COCP or VIVS? Cocrystal Pharma presently has a consensus target price of $7.00, suggesting a potential upside of 326.83%. Given Cocrystal Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Cocrystal Pharma is more favorable than Organovo.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Organovo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation and earnings, COCP or VIVS? Cocrystal Pharma has higher earnings, but lower revenue than Organovo. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCocrystal PharmaN/AN/A-$17.98M-$1.57-1.04Organovo$122K27.77-$19.31M-$10.20-0.18 Do institutionals and insiders believe in COCP or VIVS? 6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 8.2% of Organovo shares are owned by institutional investors. 28.1% of Cocrystal Pharma shares are owned by insiders. Comparatively, 3.7% of Organovo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer COCP or VIVS? In the previous week, Cocrystal Pharma had 9 more articles in the media than Organovo. MarketBeat recorded 9 mentions for Cocrystal Pharma and 0 mentions for Organovo. Cocrystal Pharma's average media sentiment score of 0.70 beat Organovo's score of 0.00 indicating that Cocrystal Pharma is being referred to more favorably in the media. Company Overall Sentiment Cocrystal Pharma Positive Organovo Neutral Which has more risk and volatility, COCP or VIVS? Cocrystal Pharma has a beta of 2.13, meaning that its share price is 113% more volatile than the S&P 500. Comparatively, Organovo has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Is COCP or VIVS more profitable? Organovo's return on equity of 0.00% beat Cocrystal Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Cocrystal PharmaN/A -94.62% -78.24% Organovo N/A N/A N/A Does the MarketBeat Community believe in COCP or VIVS? Cocrystal Pharma received 24 more outperform votes than Organovo when rated by MarketBeat users. CompanyUnderperformOutperformCocrystal PharmaOutperform Votes2477.42% Underperform Votes722.58% OrganovoN/AN/A SummaryCocrystal Pharma beats Organovo on 10 of the 15 factors compared between the two stocks. Get Organovo News Delivered to You Automatically Sign up to receive the latest news and ratings for VIVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIVS vs. The Competition Export to ExcelMetricOrganovoBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$3.39M$28.93M$2.01B$8.56BDividend YieldN/AN/A2.63%4.19%P/E Ratio-0.18N/A22.5719.93Price / Sales27.7727.7659.24147.54Price / CashN/AN/A51.7234.64Price / BookN/AN/A2.094.61Net Income-$19.31MN/A-$292.00M$248.13M7 Day Performance-6.28%7.72%1.06%1.41%1 Month PerformanceN/A-66.75%7.10%7.67%1 Year PerformanceN/A-84.62%14.12%10.04% Organovo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIVSOrganovoN/A$1.79+2.3%N/AN/A$3.39M$122,000.00-0.1820COCPCocrystal Pharma2.6263 of 5 stars$1.42-2.7%$7.00+393.0%-26.7%$14.44MN/A-0.7710Gap UpALLRAllarity Therapeutics0.7149 of 5 stars$0.95-7.8%N/A-95.2%$14.33MN/A0.0010News CoveragePositive NewsShort Interest ↓Gap DownMEIPMEI Pharma2.0986 of 5 stars$2.15-0.5%N/A-22.4%$14.32M$65.30M-0.38100Positive NewsEQEquillium2.9956 of 5 stars$0.40-1.5%$3.00+650.0%-75.3%$14.29M$30.41M-2.8640News CoveragePositive NewsShort Interest ↓EDSAEdesa Biotech3.2631 of 5 stars$2.01+2.6%$21.00+944.8%-54.0%$14.12MN/A-1.0720Positive NewsGap UpALVRAlloVirN/A$2.79-1.4%N/A-83.3%$14.07MN/A-0.14110News CoverageHigh Trading VolumeNXTCNextCure4.3067 of 5 stars$0.49-3.1%$3.50+611.4%-68.8%$13.80MN/A-0.2490Short Interest ↑ME23andMeN/A$0.50-35.3%N/A-95.4%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeIBIOiBio1.1094 of 5 stars$0.81-1.1%$4.30+431.8%-65.5%$13.36M$375,000.000.00100Gap UpRLYBRallybio3.0179 of 5 stars$0.32-2.8%$10.00+3,025.0%-82.9%$13.32M$848,000.00-0.2040Positive News Related Companies and Tools Related Companies Cocrystal Pharma Alternatives Allarity Therapeutics Alternatives MEI Pharma Alternatives Equillium Alternatives Edesa Biotech Alternatives AlloVir Alternatives NextCure Alternatives 23andMe Alternatives iBio Alternatives Rallybio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIVS) was last updated on 6/3/2025 by MarketBeat.com Staff From Our PartnersDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind ...Altimetry | SponsoredThe Real Reason Silver Prices Are SoaringElon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organovo Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organovo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VIVS Stock Free VIVS Stock Alerts